
ACTION REQUIRED

Information on Immunoglobulin Inventory Following Results of the Request for Proposals (RFP) for Plasma-Derived Plasma Protein and Related Products (PPRP)

Customer Letter # 2023-05

2023-03-13

Dear Colleagues:

Further to [CL 2022-22](#) and [CL 2022-32](#), Canadian Blood Services would like to highlight for customers that management of immunoglobulin (Ig) brands will be dynamic and ongoing. Following previous RFPs, there was often a one-time notice of new share splits followed by a one-time transition period. In today's rapidly shifting global market, that is no longer the case.

Intravenous immunoglobulin (IVIg)

Brand share split data and target reports will be shared with customers through regular reports from your local hospital liaison specialist starting in Spring 2023. Like previous reports, these will be interactive spreadsheets that allow users to view their own share splits by hospital(s) or province. The reports also include the most current share split targets. Canadian Blood Services works hard to limit the magnitude and disruption of changing share splits and will continue to work in collaboration with hospitals (as noted below), but it should be expected that the targets will change from time to time.

At this point in time, the key considerations are as follows:

Ig brand	Comment
Privigen	Privigen's target usage will increase substantially in the months to come. Please use Privigen for any new patients or patients who are switching products.
Panzyga	Panzyga inventory will likely be depleted in June 2023. This estimate is based on current usage; if usage changes, the depletion date will change. Please aim to transition all patients off Panzyga beginning in April or May 2023.
Octagam	Octagam's target usage will decrease until the remaining inventory is depleted, likely in 2024. Please do not start any new patients on Octagam.

	Please consider whether any patients on Octagam could be easily transitioned to Privigen.
Gammagard	Gammagard's target usage will decrease. Please consider whether any patients on Gammagard could be easily transitioned to Privigen.
Gamunex	Gamunex's target usage will decrease. Please consider whether any patients on Gamunex could be easily transitioned to Privigen.

Important note for all products: Canadian Blood Services may work with selected hospitals to use more or less of certain products to help mitigate unnecessary product expiration. Customers should understand that, if they are assisting in this way, their target share split will be different than what is published in the regular reports.

Subcutaneous immunoglobulin (SCIg)

Both Cuvitru and Hizentra will be available on the Canadian Blood Services PPRP formulary. There are currently no target share splits for SCIg products, but if there are significant changes in demand, target share splits may become necessary to ensure adequate supply. Customers who plan to switch patients to Hizentra or start a number of new patients on Hizentra are advised to contact their local Canadian Blood Services distribution site as far in advance as possible regarding the required additional supply.

Cutaquig will no longer be available on the Canadian Blood Services PPRP formulary. However, inventory is estimated to last until the end of 2023. Please do **not** transition patients at this time.

As described in [CL 2022-22](#), patients who have a true medical need for products no longer on formulary have the option of requesting exceptional access using the *Request for Patient Designated Plasma Protein and Related Products* form.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospital Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier
Director, Plasma Protein and Related Products Formulary Program